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Abstract 
 
Hypospadias is a common congenital malformation of the male external genitalia. We 
performed a genome-wide association study using pooled DNA from 436 individuals with 
hypospadias (cases) and 494 controls of European descent and selected the highest ranked 
SNPs for individual genotyping in the discovery sample, an additional Dutch sample of 133 
cases and their parents, and a Swedish series of 266 cases and 402 controls. Individual 
genotyping of two SNPs (rs1934179 and rs7063116) in DGKK, encoding diacylglycerol kinase κ, 
produced compelling evidence for association with hypospadias in the discovery sample (allele-
specific odds ratio (OR) = 2.5, P = 2.5 × 10-11 and OR = 2.3, P = 2.9 × 10-9, respectively) and in the 
Dutch (OR = 3.9, P = 2.4 × 10-5 and OR = 3.8, P = 3.4 × 10-5) and Swedish (OR = 2.5, P = 2.6 × 10-8 
and OR = 2.2, P = 2.7 × 10-6) replication samples. Expression studies showed expression of 
DGKK in preputial tissue of cases and controls, which was lower in carriers of the risk allele of 
rs1934179 (P = 0.047). We propose DGKK as a major risk gene for hypospadias. 
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Article 
 
Hypospadias is a common congenital hypoplasia of the penis, affecting approximately 1 in 750 
births in Europe (see URLs). Due to developmental arrest of urethral fusion, the urethral 
opening is displaced along the ventral side of the penis. The opening can be located glandular, 
penile or even more posterior in the scrotum or perineum. Although most children with this 
condition undergo surgery in their second year of life, serious medical, social and sexual 
problems may still exist later in life. Hypospadias shows familial clustering1, pointing toward 
genetic factors being important in its etiology2. Hypotheses about the multifactorial etiology of 
hypospadias mainly focus on hormonal disturbances. Polymorphisms in endocrine-related 
genes have been associated with hypospadias3-11. However, most of these associations have 
been found in small studies and were not replicated in the series used in the present study12. 
Therefore, our understanding of the molecular pathways leading to hypospadias is incomplete.  
 
With the availability of SNP microarrays, genome-wide association studies (GWASs) have 
become feasible in elucidating the genetic basis of common complex disorders. Large sample 
sizes are needed in GWASs to detect genetic factors with modest effects on disease risk, having 
substantial implications in terms of costs. A useful solution is offered by DNA pooling, which 
has been proven to be feasible and accurate13-15. 
 
To identify genetic variants contributing to hypospadias susceptibility, we performed the first 
GWAS for this malformation using pooled DNA samples. We included 436 cases of European 
descent with isolated anterior or middle hypospadias from the AGORA (Aetiologic research into 
Genetic and Occupational/environmental Risk factors for Anomalies in children) project 
(Supplementary Fig. 1 and Supplementary Table 1) and 494 unaffected male controls of 
European descent from the Nijmegen Biomedical Study. In this discovery sample, we 
allelotyped 906,600 SNPs in duplicate using Affymetrix GeneChip 6.0 microarrays and 
calculated allele frequencies using k-corrected signal intensities (see Supplementary Note). The 
worst performing 5% of measurements, indicated by the biggest differences between the allele 
frequency estimates from the duplicate measurements, were excluded. Furthermore, we 
excluded SNPs based on several quality control criteria, such as high variance in case or control 
pools and minor allele frequencies (MAF) below 5%. A total of 574,400 SNPs passed quality 
control steps and were included in the analyses. We selected the 50 highest ranked SNPs based 
on the standard χ2 statistic and a modified χ2 statistic16 applied to the raw and k-corrected 
allele frequency estimates. Of these 50 SNPs, we chose 20 based on several criteria, such as 
location near a gene and MAF (Supplementary Table 2). Seven of these 20 SNPs were located in 
the X-chromosomal gene DGKK, encoding diacylglycerol kinase κ. As most SNPs in this gene are 
in strong linkage disequilibrium (LD) with each other (Supplementary Fig. 2), we selected the 
intronic SNP that tagged the most other SNPs (rs1934179) for individual genotyping in the 
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discovery sample, as well as a potentially regulatory SNP in the 5’ upstream region (rs7063116). 
Furthermore, nine SNPs in other genes were individually genotyped (Supplementary Table 3).  
 
 
Table 1.  Association of hypospadias with SNPs in DGKK in the discovery sample, the 
Dutch replication sample and the Swedish replication sample. 
Study population 
 
 
rs1934179 in DGKK 
 
 
 
rs7063116 near DGKK 
 
OR   (95% CI) 
 
χ2 P 
 
 
 
OR    (95% CI) 
 
 
χ2 P 
 
 
Dutch discovery sample 2.46  (1.88-3.21) 2.5×10-11  2.25  (1.72-2.96) 2.9×10-9 
 
Dutch replication sample 3.92  (2.08-7.38) 2.4×10-5  3.83   (2.03-7.24) 3.4×10-5 
 
Swedish replication sample 2.48 (1.80-3.42) 2.6×10-8  2.16   (1.56-2.99) 2.7×10-6 
OR, odds ratio; CI, confidence interval. 
 
 
Individual genotyping was completed with a success rate of ≥99%. All genotype frequencies in 
the controls were in Hardy-Weinberg equilibrium (P > 0.05). Both SNPs in DGKK showed 
genome-wide significant association in the discovery sample (OR for the A (risk) allele of these 
X-chromosomal SNPs in our male sample = 2.5, P = 2.5 × 10-11 for rs1934179 and OR = 2.3, P = 
2.9 × 10-9 for rs7063116) (Table 1). These results were validated by genotyping the parents of 
the cases using the transmission disequilibrium test, a method robust to population 
stratification (Table 2). Eight of the other nine SNPs showed suggestive association with 
hypospadias (P < 0.05) (Supplementary Table 4). 
 
 
Table 2.  Association of hypospadias with SNPs in DGKK in cases in the discovery sample 
and their parents. 
 
SNP 
 
 
Minor allelea 
 
 
T 
 
 
NT 
 
 
OR  (95% CI) 
 
 
χ2 P 
 
 
rs1934179 in DGKK A 147 58 2.53 (1.87-3.43) 2.0×10-9 
 
rs7063116 near DGKK A 134 65 2.06 (1.53-2.77) 1.7×10-6 
aThe least frequent allele in the controls of the discovery sample; NT, minor allele not transmitted; T, 
minor allele transmitted; OR, odds ratio; CI, confidence interval. 
 
 
For the ten associated SNPs, we subsequently attempted replication in an additional Dutch 
sample of 133 anterior or middle hypospadias cases of European descent and their parents. 
Seven SNPs showed similar ORs in this sample compared to the discovery sample, although 
most of these SNPs did not reach statistical significance, probably due to the small number of 
heterozygous parents. The only exceptions to this were the SNPs in DGKK, in which the same A 
alleles were again strongly associated with hypospadias (OR = 3.9, P = 2.4 × 10-5 for rs1934179 
and OR = 3.8, P = 3.4 × 10-5 for rs7063116) (Table 1 and Supplementary Table 5). A second 
replication in a Swedish cohort of 266 anterior or middle hypospadias cases and 402 male 
controls convincingly confirmed the associations with the A alleles of the SNPs in DGKK (OR = 
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2.5, P = 2.6 × 10-8 for rs1934179 and OR = 2.2, P = 2.7 × 10-6 for rs7063116), whereas 
associations with the other eight SNPs did not reach statistical significance (Table 1 and 
Supplementary Table 6). We then performed a meta-analysis with both the discovery sample 
and the two replication samples (Supplementary Table 7). In addition to the SNPs in DGKK, 
SNPs in PPARGC1B (rs4705372) and GRID1 (rs1880386) reached statistical significance in this 
analysis after correcting the critical P value for multiple testing (critical Bonferroni P < 0.005).  
 
The pathogenesis of hypospadias probably includes many causal factors. We calculated the 
population attributable fraction (PAF) for hypospadias of rs1934179 in DGKK to be 32% in the 
Dutch population and 31% in the Swedish population, meaning that the variant underlying the 
association between rs1934179 in DGKK and hypospadias is one of the causal factors in nearly 
one third of hypospadias cases. As a comparison, the PAF for APOE in Alzheimer’s disease is 
26% (ref. 17), and that association is one of the strongest and best known genetic associations 
reported for a multifactorial disorder. However, the PAF calculated for hypospadias is based on 
data from our study only, and independent population-based studies should be performed to 
verify the validity of the estimate. 
 
DGKK encodes a human type II diacylglycerol kinase18. Diacylglycerol kinases modulate the 
balance between diacylglycerol and phosphatidic acid, two signaling lipids, thereby playing an 
important role in signal transduction. DGKK mRNA is most abundant in testis and placenta18. 
Although DGKK has not previously been associated with hypospadias and there are other genes 
in close proximity to it, we suggest DGKK as the hypospadias susceptibility gene in the 
identified X-chromosomal locus as the LD block in which the gene is located encompasses only 
DGKK (Supplementary Fig. 2). Because the LD block also covers likely regulatory regions, 
variants regulating DGKK expression may underlie the association of DGKK with hypospadias. 
We performed real-time quantitative PCR analyses showing that DGKK is expressed in preputial 
skin of all investigated healthy boys (n = 10) and of hypospadias cases (n = 14) (Supplementary 
Fig. 3). Expression was lower in individuals with the A (risk) allele (n = 15) of rs1934179 (P = 
0.047) (Fig. 1). These results suggest that variants regulating DGKK mRNA expression underlie 
the association of rs1934179 with hypospadias. A search for potential functional variants 
identified one SNP in a FOXL1 transcription factor binding site, rs1934176, which is in high LD 
(r2 = 0.99) with rs1934179; however, the significance of this SNP requires further study. 
 
SNPs in GRID1, PPARGC1B and KIAA2022 showed associations in the same direction in the 
discovery sample and in both replication samples, resulting in outcomes with a higher level of 
statistical significance in the meta-analysis. This suggests that nonsignificance of results may be 
due to lack of power. Indeed, the power of our study to detect associations with OR < 1.5 was 
limited and was even further reduced by the fact that we used DNA pooling. Using DNA pools 
instead of individual DNA samples results in less accurate allele frequency estimates, possibly 
producing more false-positive and false-negative findings. Validating our results by individual 
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genotyping enabled us to identify false-positive findings arising from such inaccurate estimates. 
False-negative results cannot be identified, however, and we may have missed additional 
associations that we would have detected with a GWAS based on individual genotyping. In 
addition, we may have missed associations with rare variants by excluding SNPs with MAF 
below 5%, that is, SNPs for which we had insufficient power. Therefore, individual GWAS 
(preferentially in larger samples) may identify additional hypospadias loci. 
 
 
Figure 1.  Quantification of DGKK mRNA expression (± s.e.m.) in preputial skin of 
hypospadias cases and controls relative to GAPDH mRNA expression. 
 
 
 
Previously performed studies showed familial occurrence of hypospadias for anterior and 
middle forms of hypospadias but not for posterior types1,19. Because of this apparent etiologic 
heterogeneity, we included only anterior and middle cases in the current analyses. As 
expected, an additional analysis of the SNPs in DGKK in cases with posterior hypospadias 
showed weaker associations (Table 3), although the small number of cases used may have 
hampered a fair comparison. Nevertheless, these data are compatible with anterior and middle 
forms of hypospadias having an oligogenic or polygenic multifactorial etiology, including a 
crucial role for DGKK, and with posterior forms having a different etiology. These results 
warrant stratification by hypospadias phenotype based on location of the urethral opening in 
future genetic studies, which may reduce genetic heterogeneity and improve the 
reproducibility of the results. 
 
In summary, we have identified a new X-chromosomal risk locus for hypospadias. We showed 
expression of DGKK in preputial skin, which was lower in boys with the risk allele. We propose 
DGKK as a major risk gene for anterior and middle forms of hypospadias. Because hypospadias 
is a fusion defect, DGKK might be important for other congenital closure defects as well. 
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Table 3.  Association of different forms of hypospadias with SNPs in DGKK. 
 
Study population 
(ncontrols/ncases) 
 
 
Minor allele (A) frequency (%) 
 
  
 
Controls 
 
Cases 
 
OR   (95% CI) 
 
χ2 P 
 
 
rs1934179 in DGKK 
  
   
 
Dutch sample    
 
 
Anterior and middle cases (494/436)  
(cases used in the discovery sample) 32.9 54.6 2.46  (1.88-3.21)  2.5×10-11 
 
Posterior cases (494/87) 32.9 38.1 1.26  (0.78-2.03)    0.348 
 
Swedish sample    
 
Anterior and middle cases (402/266) 
(cases used in the replication sample) 31.0 52.7 2.48 (1.80-3.42)  2.6×10-8 
 
Posterior cases (402/62) 31.0 45.9 1.89  (1.09-3.26)    0.021 
 
rs7063116 near DGKK 
 
 
Dutch sample     
 
 
Anterior and middle cases (494/436) 
(cases used in the discovery sample) 29.3 48.3 2.25  (1.72-2.96)  2.9×10-9 
 
Posterior cases (494/87) 29.3 26.2 0.86  (0.51-1.45)    0.565 
 
Swedish sample     
 
Anterior and middle cases (402/266) 
(cases used in the replication sample) 29.4 47.3 2.16  (1.56-2.99)  2.7×10-6 
 
Posterior cases (402/62) 
 
29.4 
 
41.0 
 
1.67  (0.96-2.91) 
 
   0.067 
 
OR, odds ratio; CI, confidence interval. 
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Online methods 
 
Pool construction 
The AGORA (Aetiologic research into Genetic and Occupational/environmental Risk factors for 
Anomalies in children) project of the Radboud University Nijmegen Medical Centre (RUNMC), 
Nijmegen, The Netherlands, is building a data bank and bio bank with questionnaire data and 
DNA samples from individuals with a congenital malformation or childhood cancer, as well as 
their parents. DNA was available for 679 hypospadias cases from the AGORA project 
(Supplementary Fig. 1 and Supplementary Table 1) and 596 unaffected male controls of 
European descent from the Nijmegen Biomedical Study20. The Arnhem-Nijmegen Regional 
Committee on Research Involving Human Subjects approved both studies. All participants 
and/or their parents gave written informed consent for participation in the studies. A detailed 
description of the study populations and pooling process can be found in the Supplementary 
Note. Finally, DNA samples of 436 cases of European descent with isolated anterior or middle 
hypospadias and 494 unaffected male controls of European descent were pooled in eight case 
pools and eight control pools. 
 
Genome-wide analysis  
We allelotyped each pool in duplicate using Affymetrix GeneChip 6.0 microarrays containing 
906,600 polymorphic SNPs. Array experiments were performed according to protocols 
provided by the manufacturer. We used the SNPMaP package21 in the statistical software 
program R (see URLs) to calculate relative allele signal (RAS) scores and k-corrected raw allele 
frequency (RAFk) estimates for each SNP, as is described in the Supplementary Note.   
 
A total of 574,400 SNPs passed quality control steps (described in the Supplementary Note) 
and were included in the association analyses. We averaged data across case pools and control 
pools separately to obtain RAFk and RAS estimates for cases and controls. We subsequently 
calculated the modified χ2 statistic16, which is expressed as: 
                        Pcases - Pcontrols 
Z =  
                           Pp × (1 - Pp) × (1 / 2Ncases + 1 / 2Ncontrols) + σ
2
pool × (1 / npcases + 1 / npcontrols) 
 
Where Pcases is the allele frequency estimate (RAFk) in the case pools, Pcontrols is the RAFk in the 
control pools and Pp is an estimate of the allele frequency in the population, for which we used 
the allele frequency in 603 individually genotyped in-house controls of European descent22. 
Ncases is the number of individuals in the case pools and Ncontrols is the number of individuals in 
the control pools, taking into account the loss of cases and controls after the quality control. A 
SNP-specific variance calculated across the two measurements for each DNA pool was 
averaged across the pools to obtain σ2pool. Finally, npcases and npcontrols are the number of 
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measurements (pools) for the case and control pools. We selected the 5,000 SNPs with the 
highest Z scores, and calculated two additional statistics for these SNPs: the standard χ2 
statistic using the expected numbers of alleles in the cases and controls calculated from the 
RAFk estimates and the adjusted χ
2 statistic using the RAS values. Combining the results from all 
three statistics enabled us to select the most promising SNPs. 
 
We used several criteria to select SNPs from the pooled GWAS as eligible for individual 
genotyping in the discovery sample to validate the results as is described in the Supplementary 
Note. Ultimately, 20 SNPs were eligible. As seven of these 20 SNPs were SNPs in high LD within 
DGKK (Supplementary Fig. 2), we genotyped  the SNP that tagged most of the other SNPs 
(rs1934179, an intronic SNP). In addition, we genotyped a potentially regulatory SNP in the 5’ 
upstream region (rs7063116).  
 
Validation of the results from the pooled GWAS 
Taqman SNP genotyping assays could not be designed for four of the 15 SNPs that were 
selected for individual genotyping in the discovery sample. We excluded these SNPs from 
further analysis. The other 11 SNPs (Supplementary Table 3) were individually genotyped using 
5’ nuclease TaqMan SNP genotyping assays (Supplementary Table 8). In each 96-well plate, we 
loaded five wells with randomly selected duplicate DNA samples from the same and other 
plates for quality control purposes. In addition, we included four blanks in each plate. 
Genotyping was completed with a success rate of at least 99%.  
 
All genotype frequencies in controls were in Hardy-Weinberg equilibrium, with P values 
ranging from 0.34 to 0.94. For the genotyped SNPs, we calculated ORs for hypospadias risk and 
the corresponding 95% confidence intervals (CIs) at a genotypic and an allelic level using the 
most frequent homozygous genotypes in controls as reference values. Furthermore, we 
performed χ2 tests. When the expected cell numbers were below five, exact 95% CIs around 
the ORs were calculated using the Fisher exact method. Ten of the associations were 
statistically significant (P < 0.05), but only the association with the two SNPs in the X-
chromosomal DGKK gene reached genome-wide significance (P < 5.0 × 10-8) (Supplementary 
Table 4). These results were validated by genotyping the parents of the cases. For these case-
parent triads, we used the transmission disequilibrium test (TDT)23 for statistical analysis of the 
data with the software program Haploview 4.1 (ref.24). Furthermore, we calculated the ORs for 
hypospadias risk and corresponding 95% CIs at the allelic level25 (Table 2). 
 
Replication studies 
A detailed description of the study populations can be found in the Supplementary Note. The 
Arnhem-Nijmegen Regional Committee on Research Involving Human Subjects and the Ethics 
Committee at Karolinska Institutet approved the studies and all participants and/or their 
parents gave written informed consent for participation in the studies. 
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For the Dutch replication sample, we genotyped 133 cases of European descent with isolated 
anterior or middle hypospadias and their parents for the SNPs that were associated with 
hypospadias in the individually genotyped discovery sample (P < 0.05). Genotyping was 
completed with a success rate of at least 95%. All genotype frequencies in the parents were in 
Hardy-Weinberg equilibrium (with P values ranging from 0.16 to 0.99). For these case-parent 
triads, we again used the TDT23 for statistical analysis of the data with the software program 
Haploview 4.1 (ref.24), and we calculated the ORs for hypospadias risk and the corresponding 
95% CIs at the allelic level25 (Supplementary Table 5).  
 
For the Swedish replication sample, we genotyped 266 Swedish cases with anterior or middle 
hypospadias and 402 male Swedish controls for the SNPs that were associated with 
hypospadias in the individually genotyped discovery sample (P < 0.05). Genotyping was 
completed with a success rate of at least 98%. All genotype frequencies in the controls were in 
Hardy-Weinberg equilibrium (with P values ranging from 0.13 to 0.99), except for rs1022357 in 
SLCO3A1 (P = 0.01). However, after correcting the critical P value for multiple testing, this 
result did not reach statistical significance (critical Bonferroni P < 0.005). We calculated ORs for 
hypospadias risk and the corresponding 95% CIs at genotypic and allelic level, performed χ2 
tests and calculated exact 95% CIs around the ORs using the Fisher exact method when 
expected cell numbers were below five (Supplementary Table 6).  
 
Meta-analysis 
We combined the results of both the discovery sample and the two replication samples in a 
meta-analysis in Review Manager 5 (see URLs) using the inverse-variance method and random 
effects models (Supplementary Table 7). 
 
Expression of DGKK 
We isolated RNA from preputial skin samples from 14 hypospadias cases and ten age-matched 
controls. The origin of the samples and the methods used are described in the Supplementary 
Note. We performed RT-PCR according to the standard protocol as described in the 
Supplementary Note. Expression levels of DGKK were reported relative to GAPDH. We also 
genotyped DNA samples for the two SNPs in DGKK and compared relative gene expression 
levels between boys with the G allele (45.9% of GAPDH, n = 9) and the A (risk) allele (40.1% of 
GAPDH, n = 15) of the X-chromosomal SNP rs1934179 in DGKK using the independent samples 
t test. 
 
Search for potential functional variants 
We searched different databases, such as dbSNP and HapMap, for nonsynonymous SNPs that 
might be causative variants, taking validation of the SNPs, conservation of amino acids, and 
Grantham scores of amino acid replacements into account. Concerning non-coding areas, we 
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used the UCSC genome browser to check for microRNA binding sites, enrichments of histone 
marks associated with enhancers or promoters, and for transcription factor binding sites. 
 
Calculation of Population Attributable Fraction 
We calculated the population attributable fraction (PAF) as26: 
 
    q (OR - 1)  
PAF =  
  q (OR - 1) + 1 
 
where OR is the odds ratio and q is the proportion of exposed individuals (proportion of 
individuals with the risk allele) in the control group, which is the A allele of rs1934179 in DGKK.  
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Suppl. figure 3.  Quantification of DGKK mRNA expression (± s.e.m.) in preputial skin of 
hypospadias cases and controls relative to GAPDH mRNA expression. 
Relative gene expression levels were compared between cases (43.1% of 
GAPDH, n = 14) and controls (41.2% of GAPDH, n = 10) using the 
independent samples t-test. 
 
 
 
 
Supplementary tables 
 
Suppl. table 1.  Clinical characteristics of the hypospadias patients in the discovery sample. 
 
 
Anatomical location of urethral opening 
 
 
 
Anterior n=318 (73%) 
 
 
 
Middle n=118 (27%) 
 
 
HsH 
 
 
Glandular 
 
(Sub)-
coronal 
 
 
 
Distal 
penile 
 
 
Midshaft 
 
 
Proximal 
penile 
 
 
Total 33 88 197  63 48   7 
 
 Chordee 21 (64%) 30 (34%) 115 (58%)  41 (65%) 38 (79%)                       6 (86%) 
 Cryptorchidisma   4 (12%)   2    (2%)   11    (6%)    3    (5%)   1    (2%)   0 
 Other deformitiesb   4 (12%) 10 (11%)     8    (4%)    4    (6%)   0    0  
HsH, Hypospadias sine hypospadias; aincluding only cases that underwent orchidopexy or 
orchidectomy; bincluding cases with heart-, renal- and gastro-intestinal deformities, neural tube 
defects, cleft lip and/or palate and deformities of the lower extremities. 
 
 
Suppl. table 2.  SNPs appearing in the top 200 ranks for all three statistical tests used. The 
grey-shaded SNPs are the SNPs that were selected based on the criteria 
used. As seven of these 20 SNPs were SNPs in high LD within the DGKK gene, 
we selected the SNP that tagged most of the other SNPs (rs1934179) for 
individual genotyping in the discovery sample. In addition, we genotyped a 
potentially regulatory SNP in the 5’-upstream region (rs7063116). Taqman 
SNP genotyping assays could not be designed for four of the fifteen SNPs 
that were thus selected for individual genotyping in the discovery sample. 
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Suppl. table 2. 
SNP 
 
Chr 
 
 
Rank 
adj  
χ2-test  
using 
RAS 
 
 
Rank 
adj  
χ2-test  
using 
RAFk 
 
 
Rank  
χ2-test 
using 
RAFk 
 
Nearest gene 
 
Location 
 
 
MAF in  
 in-
house 
control 
samples 
 
 
Sup-
porting 
evidence 
from 
SNPs in 
LDa 
 
 
Reason 
exclusion 
from 
individual 
geno-
typing 
 
 
rs1934179 X       46   21      4 DGKK intron 0.337 yes  
rs16985967 22       26     4    12 TTC28 intron 0.080 yes  
rs7085066 10       35    19    31 SLC16A12 intron 0.105 yes  
rs1022357 15     199 176    79 SLCO3A1 intron 0.166 yes  
rs10184015 2       32   17    83 SOS1 intron 0.066 yes  
rs6607499 X       38   33  133 KIAA2022 12 kb up 0.065 yes  
rs4705372 5     165 119  168 PPARGC1B intron 0.123 yes  
rs3755071 2       31   81    16 SRBD1 intron 0.226 -  
rs1880386 10     180   42    35 GRID1 intron 0.152 -  
rs12660161 6       30   11    56 MTHFD1L 39 kb down 0.085 -  
rs7896487 10       19 144    55 CDH23 intron 0.123 - assay 
rs9735061 11       73 186  139 FAM86A 43 kb up 0.122 - assay 
rs7321040 13       21   13    75 DIAPH3 31 kb down 0.055 - assay 
rs10997978 10       28     2    26 MYPN intron 0.056 yes assay 
rs1934171 X         3     1      1 DGKK intron 0.336 yes other SNP 
rs1934188 X       52     5      2 DGKK intron 0.314 yes other SNP 
rs1934176 X         8     3      3 DGKK intron 0.337 yes other SNP 
rs4826629 X       99   79      5 DGKK intron 0.316 yes other SNP 
rs1934175 X       77   57      8 DGKK intron 0.336 yes other SNP 
rs17281440 X     182 169    34 DGKK intron 0.240 yes other SNP 
rs17051831 13       85   95  118 NBEA intron 0.096 - LD/MAF 
rs7229296 18     126 103  137 RAB31 9 kb down 0.092 - LD/MAF 
rs4869674 5       13   27    32 SPEF2 intron 0.091 - LD/MAF 
rs17126762 1       34   14    80 CACHD1 intron 0.072 - LD/MAF 
rs17021660 4       16     9    22 POU4F2 17 kb up 0.062 - LD/MAF 
rs527834 15     193   18    13 CHRM /AVEN intron 0.053 - LD/MAF 
rs16841107 1     196   88    69 RGS7 intron 0.050 - LD/MAF 
rs12465925 2     191 151    72 TMEFF2 intron 0.132 no LD 
rs17236770 15     135 106    21 TMEM85 intron 0.123 no LD 
rs3771698 2         9   32    17 BAZ2B intron 0.088 no LD 
rs16842909 2       83   50    97 MAP2 intron 0.072 no LD 
rs764125 3       78   40  146 CMTM8 intron 0.057 no LD 
rs9308056 4         6   93  172 TKTL2 54 kb down 0.083 yes distance 
rs2114929 5       48 102    62 TARS 63 kb up 0.141 yes distance 
rs1560398 18       10     8    40 MC4R 123 kb up 0.063 - distance 
rs1397151 16       79    39    76 CES7 130 kb up 0.057 yes distance 
rs16888346 4       63   38    18 HSP90AB2P 135 kb up 0.113 - distance 
rs6847625 4         5   10    52 GPRIN3 197 kb up 0.069 - distance 
rs10497759 2       81   72      6 SLC39A10 244 kb up 0.297 - distance 
rs2174232 10       53   37    67 ZWINT 816 kb up 0.070 - distance 
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 Suppl. table 2. (continued) 
SNP 
 
Chr 
 
 
Rank 
adj  
χ2-test  
using 
RAS 
 
 
Rank 
adj  
χ2-test  
using 
RAFk 
 
 
Rank  
χ2-test 
using 
RAFk 
 
Nearest gene 
 
Location 
 
 
MAF in  
 in-
house 
control 
samples 
 
 
Sup-
porting 
evidence 
from 
SNPs in 
LDa 
 
 
Reason 
exclusion 
from 
individual 
geno-
typing 
 
 
rs6127262 20     101 185  100 DOK5 62 kb down 0.010 - distance 
rs4850833 2       98   69    64 PLCL1 73 kb down 0.114 yes distance 
rs12544855 8       86   45    70 LOC100129963 87 kb down 0.100 - distance 
rs16864680 2         4   23  164 LOC400940 91 kb down 0.080 - distance 
rs10733948 10     176 107  142 ZWINT 131 kb down 0.095 no distance 
rs2468265 12     177 110      7 SUDS3 199 kb down 0.477 - distance 
rs10024666 4       57   35  175 TRAM1L1 314 kb down 0.078 - distance 
rs12265647 10       17   16  182 YWHAZ 321 kb down 0.070 - distance 
rs11046765 12         1     6    33 ETNK1 356 kb down 0.061 yes distance 
rs5942497 X     120 104  157 CPXCR1 574 kb down 0.063 no distance 
Chr, chromosome; adj, adjusted; RAS, relative allele signal; RAFk, k-corrected raw allele frequency 
estimate; MAF, minor allele frequency; LD, linkage disequilibrium; kb, kilobases; up, upstream; down, 
downstream; assay, assay unavailable; other SNP, other SNP in gene; LD/MAF, LD and MAF < 0.10; 
distance, gene distance;  ayes = supporting evidence defined as at least half of the SNPs in high LD (r2 
> 0.8) having a low average P-value (< 0.22, the 10th percentile of the average P-values of all 574,400 
SNPs), no = reduced evidence defined as at least half of the SNPs in high LD having a high average P-
value, - = no SNPs in high LD. 
 
 
Suppl. table 3. Single nucleotide polymorphisms individually genotyped in the discovery 
sample. 
 
SNP  
 
 
Chr 
 
 
Nearest gene 
 
 
Location 
 
 
rs1934179 X DGKK intron 
 
rs7063116 X DGKK 21 kb upstream 
 
rs1880386 10 GRID1 intron 
 
rs6607499 X KIAA2022 12 kb upstream 
 
rs12660161 6 MTHFD1L 39 kb downstream 
 
rs4705372 5 PPARGC1B intron 
 
rs7085066 10 SLC16A12 intron 
 
rs1022357 15 SLCO3A1 intron 
 
rs10184015 2 SOS1 intron 
 
rs3755071 2 SRBD1 intron 
 
rs16985967 22 TTC28 intron 
Chr, chromosome. 
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Suppl. table 4.  Association analyses with hypospadias for single nucleotide polymorphisms 
in selected genes in the discovery sample. 
 
 
Controls 
n=494 
     n (%) 
 
Cases 
n=436 
    n (%) 
 
 
  OR (95% CI) 
 
 
χ2 P 
 
Controls 
n=494 
    n (%) 
Cases 
n=436 
    n (%) 
 
 
  OR (95% CI) 
 
 
χ2 P 
 
Allele frequencies 
 
 
Genotype frequencies 
 
 
rs1934179 in DGKK       
G  331 (67) 196 (45) 1.00 (ref) ref Not applicable, X-chromosomal SNP 
A  162 (33) 236 (55) 2.46 (1.88-3.21) 2.5×10-11      
 
rs7063116 near DGKK       
G  348 (71) 224 (52) 1.00 (ref) ref Not applicable, X-chromosomal SNP 
A  144 (29) 209 (48) 2.25 (1.72-2.96) 2.9×10-9      
 
rs1880386 in GRID1      
C  844 (86) 698 (81) 1.00 (ref) ref CC 360 (73) 285 (66) 1.00 (ref) ref 
T  140 (14) 162 (19) 1.40 (1.09-1.79) 0.008 CT 124 (25) 128 (30) 1.30 (0.97-1.75) 0.075 
     TT     8   (2)   17   (4) 2.68 (1.14-6.31) 0.019 
 
rs6607499 near KIAA2022      
G  474 (96) 402 (93) 1.00 (ref) ref Not applicable, X-chromosomal SNP 
A    18  (4)   31   (7) 2.03 (1.12-3.68) 0.018      
 
rs12660161 near MTHFD1L      
G  909 (92) 766 (88) 1.00 (ref) ref GG 419 (85) 343 (79) 1.00 (ref) ref 
A    79   (8) 100 (12) 1.50 (1.10-2.05) 0.010 AG   71 (14)   80 (18) 1.38 (0.97-1.95) 0.073 
     AA     4   (1)   10   (2) 3.05 (0.95-9.82) 0.049 
 
rs4705372 in PPARGC1B      
G  856 (87) 714 (82) 1.00 (ref) ref GG 371 (75) 298 (69) 1.00 (ref) ref 
A  132 (13) 154 (18) 1.40 (1.09-1.80) 0.009 AG 114 (23) 118 (27) 1.29 (0.96-1.74) 0.096 
     AA     9   (2)   18   (4) 2.49 (1.10-5.62) 0.024 
 
rs7085066 in SLC16A12      
G  898 (91) 769 (89) 1.00 (ref) ref GG 409 (83) 338 (78) 1.00 (ref) ref 
C    90   (9)   95 (11) 1.23 (0.91-1.67) 0.177 CG   80 (16)   93 (22) 1.41 (1.01-1.96) 0.043 
     CC     5   (1)     1   (0) 0.24 (0.01-2.18)a 0.325 
 
rs1022357 in SLCO3A1      
A  824 (84) 689 (79) 1.00 (ref) ref AA 344 (70) 277 (64) 1.00 (ref) ref 
G  162 (16) 179 (21) 1.32 (1.04-1.67) 0.020 AG 136 (28) 135 (31) 1.23 (0.93-1.64) 0.151 
     GG   13   (3)   22   (5) 2.10 (1.04-4.25) 0.035 
 
rs10184015 in SOS1      
G  923 (93) 781 (90) 1.00 (ref) ref GG 430 (87) 353 (81) 1.00 (ref) ref 
A    65   (7)   87 (10) 1.58 (1.13-2.21) 0.007 AG   63 (13)   75 (17) 1.45 (1.01-2.09) 0.044 
     AA     1   (0)     6   (1) 7.31 (0.88-337)a 0.074 
 
rs3755071 in SRBD1      
A  690 (70) 652 (75) 1.00 (ref) ref AA 238 (48) 242 (56) 1.00 (ref) ref 
G  292 (30) 214 (25) 0.78 (0.63-0.95) 0.016 AG 214 (44) 168 (39) 0.77 (0.59-1.01) 0.060 
     GG   39   (8)   23   (5) 0.58 (0.34-1.00) 0.049 
 
rs16985967 in TTC28      
C  924 (94) 771 (89) 1.00 (ref) ref CC 432 (88) 339 (78) 1.00 (ref) ref 
T    62   (6)   97 (11) 1.88 (1.34-2.62) 0.0002 CT   60 (12)   93 (21) 1.98 (1.39-2.82) 0.0001 
     TT     1   (0)     2   (0) 2.55 (0.13-151)a 0.822 
OR, odds ratio; CI, confidence interval; ref, used as reference; aexact 95% CI calculated using the 
Fisher exact method. 
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Suppl. table 5. Association analyses with hypospadias for single nucleotide polymorphisms 
in selected genes in the Dutch replication sample. 
 
SNP  
 
 
Minor allelea 
 
 
NT 
 
 
T 
 
 
OR     (95%CI) 
 
 
χ2 P 
 
 
rs1934179 in DGKK A 12 47 3.92   (2.08-7.38) 2.4×10-5 
 
rs7063116 near DGKK A 12 46 3.83   (2.03-7.24) 3.4×10-5 
 
rs1880386 in GRID1  T 24 33 1.38   (0.81-2.33)   0.233 
 
rs6607499 near KIAA2022 A   6   7 1.17   (0.39-3.47)   0.782 
 
rs12660161 near MTHFD1L A 17 28 1.65   (0.90-3.01)   0.101 
 
rs4705372 in PPARGC1B A 21  31 1.48   (0.85-2.57)   0.166 
 
rs1022357 in SLCO3A1 G 28 37 1.32   (0.81-2.16)   0.264 
 
rs10184015 in SOS1 A 19 18 0.95   (0.50-1.81)   0.869 
 
rs3755071 in SRBD1 G 35 40 1.14   (0.73-1.80)   0.564 
 
rs16985967 in TTC28 T   7 14 2.00   (0.81-4.96)   0.127 
OR, odds ratio; CI, confidence interval; NT, minor allele not transmitted; T, minor 
allele transmitted; athe least frequent allele in the controls of the discovery 
sample. 
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Suppl. table 6. Association analyses with hypospadias for single nucleotide polymorphisms 
in selected genes in the Swedish replication sample. 
 
 
Controls 
n=402  
     n (%) 
 
Cases 
n=266 
    n (%) 
 
 
   OR (95% CI) 
 
 
χ2 P 
 
 
Controls 
n=402  
     n (%) 
 
Cases 
n=266 
    n (%) 
 
 
   OR (95% CI) 
 
 
χ2 P 
 
Allele frequencies 
 
 
Genotype frequencies 
 
 
rs1934179 in DGKK       
G 276 (69) 123 (47) 1.00 (ref) ref Not applicable, X-chromosomal SNP 
A 124 (31) 137 (53) 2.48 (1.80-3.42) 2.6×10-8      
 
rs7063116 near DGKK       
G 284 (71) 137 (53) 1.00 (ref) ref Not applicable, X-chromosomal SNP 
A 118 (29) 123 (47) 2.16 (1.56-2.99) 2.7×10-6      
 
rs1880386 in GRID1      
C 676 (85) 428 (82) 1.00 (ref) ref CC 288 (72) 179 (69) 1.00 (ref) ref 
T 124 (16)   92 (18) 1.17 (0.87-1.57) 0.293 CT 100 (25)   70 (27) 1.13 (0.79-1.61) 0.515 
     TT   12   (3)   11   (4) 1.47 (0.64-3.41) 0.362 
 
rs6607499 near KIAA2022      
G 372 (93) 235 (90) 1.00 (ref) ref Not applicable, X-chromosomal SNP 
A   29    (7)   27 (10) 1.47 (0.85-2.55) 0.165      
 
rs12660161 near MTHFD1L      
G 714 (89) 473 (91) 1.00 (ref) ref GG 320 (80) 213 (82) 1.00 (ref) ref 
A   84 (11)   49   (9) 0.88 (0.61-1.28) 0.502 AG   74 (19)   47 (18) 0.95 (0.64-1.43) 0.820 
     AA     5   (1)     1   (0) 0.30 (0.01-2.72)a 0.473 
 
rs4705372 in PPARGC1B      
G 709 (89) 453 (86) 1.00 (ref) ref GG 313 (78) 199 (76) 1.00 (ref) ref 
A   89 (11)   73 (14) 1.28 (0.92-1.79) 0.139 AG   83 (21)   55 (21) 1.04 (0.71-1.53) 0.833 
     AA     3   (1)     9   (3) 4.72 (1.16-27.3)a 0.027 
 
rs1022357 in SLCO3A1      
A 649 (81) 414 (81) 1.00 (ref) ref AA 271 (68) 163 (63) 1.00 (ref) ref 
G 151 (19) 100 (19) 1.04 (0.78-1.38) 0.794 AG 107 (27)   88 (34) 1.37 (0.97-1.93) 0.073 
     GG   22   (6)     6   (2) 0.45 (0.18-1.14) 0.086 
 
rs10184015 in SOS1      
G 738 (92) 477 (91) 1.00 (ref) ref GG 341 (85) 220 (84) 1.00 (ref) ref 
A   66   (8)   49   (9) 1.15 (0.78-1.69) 0.483 AG   56 (14)   37 (14) 1.02 (0.65-1.60) 0.917 
     AA     5   (1)     6   (2) 1.86 (0.47-7.79)a 0.468 
 
rs3755071 in SRBD1      
A 627 (78) 382 (75) 1.00 (ref) ref AA 241 (60) 143 (56) 1.00 (ref) ref 
G 173 (22) 130 (25) 1.23 (0.95-1.60) 0.115 AG 145 (36)   96 (38) 1.12 (0.80-1.55) 0.516 
     GG   14   (4)   17   (7) 2.05 (0.98-4.28) 0.053 
 
rs16985967 in TTC28      
C 720 (90) 467 (90) 1.00 (ref) ref CC 324 (81) 208 (80) 1.00 (ref) ref 
T   80 (10)   53 (10) 1.02 (0.71-1.47) 0.910 CT   72 (18)   51 (20) 1.10 (0.74-1.64) 0.629 
     TT     4   (1)     1   (0) 0.39 (0.01-3.98)a 0.710 
OR, odds ratio; CI, confidence interval; ref, used as reference; aexact 95% CI calculated using the 
Fisher exact method. 
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Suppl. table 7. Association analyses with hypospadias for single nucleotide polymorphisms 
in selected genes in the discovery sample, the Dutch replication sample and 
the Swedish replication sample, and results of the meta-analysis. 
  
 
Discovery sample 
  
Dutch replication sample 
 
 
MAF (%) 
 
 
 
 
  TDT 
 
 
 
SNP (minor allelea) 
 
 
Con-
trols 
n= 
494 
 
Cases 
n= 
436 
 
 
OR  (95%CI) 
 
 
χ2 P 
 
NT 
 
T 
 
 
OR  (95%CI) 
 
 
χ2 P 
 
 
rs1934179 in DGKK (A) 32.9 54.6 2.5 (1.9-3.2) 2.5×10-11 12 47 3.9 (2.1-7.4) 2.4×10-5 
 
rs7063116 near DGKK (A) 29.3 48.3 2.3 (1.7-3.0) 2.9×10-9 12 46 3.8 (2.0-7.2) 3.4×10-5 
 
rs1880386 in GRID1 (T) 14.2 18.8 1.4 (1.1-1.8)   0.008 24 33 1.4 (0.8-2.3)   0.233 
 
rs6607499 near KIAA2022 (A)   3.7   7.2 2.0 (1.1-3.7)   0.018   6   7 1.2 (0.4-3.5)   0.782 
 
rs12660161 near MTHFD1L (A)   8.0 11.5 1.5 (1.1-2.1)   0.010 17 28 1.7 (0.9-3.0)   0.101 
 
rs4705372 in PPARGC1B (A) 13.4 17.7 1.4 (1.1-1.8)   0.009 21  31 1.5 (0.9-2.6)   0.166 
 
rs7085066 in SLC16A12 (C)   9.1 11.0 1.2 (0.9-1.7)   0.177     
 
rs1022357 in SLCO3A1 (G) 16.4 20.6 1.3 (1.0-1.7)   0.020 28 37 1.3 (0.8-2.2)   0.264 
 
rs10184015 in SOS1 (A)   6.6 10.0 1.6 (1.1-2.2)   0.007 19 18 1.0 (0.5-1.8)   0.869 
 
rs3755071 in SRBD1 (G) 29.7 24.7 0.8 (0.6-1.0)   0.016 35 40 1.1 (0.7-1.8)   0.564 
 
rs16985967 in TTC28 (T)   6.3 11.2 1.9 (1.3-2.6)   0.0002   7 14 2.0 (0.8-5.0)   0.127 
  
 
 
Swedish replication sample 
 
 
 
Meta-analysis results 
 
  
 
MAF (%) 
 
  
 
 
SNP (minor allelea) 
 
 
Con-
trols 
n= 
402 
 
Cases 
n= 
266 
 
 
 OR (95%CI) 
 
 
χ2 P 
 
  
 
 OR (95%CI) 
 
 
χ2 P 
 
 
rs1934179 in DGKK (A) 31.0   52.7 2.5 (1.8-3.4) 2.6×10-8   2.6 (2.1-3.1) 2.8×10-21 
 
rs7063116 near DGKK (A) 29.4   47.3 2.2 (1.6-3.0) 2.7×10-6   2.4 (1.9-3.0) 1.2×10-12 
 
rs1880386 in GRID1 (T) 15.5   17.7 1.2 (0.9-1.6)   0.293   1.3 (1.1-1.6)   0.003 
 
rs6607499 near KIAA2022 (A)   7.2   10.3 1.5 (0.9-2.6)   0.165   1.6 (1.1-2.4)   0.011 
 
rs12660161 near MTHFD1L (A) 10.5     9.4 0.9 (0.6-1.3)   0.502   1.3 (0.9-1.9)   0.242 
 
rs4705372 in PPARGC1B (A) 11.2   13.9 1.3 (0.9-1.8)   0.139   1.4 (1.1-1.7)   0.001 
 
rs7085066 in SLC16A12 (C)         
 
rs1022357 in SLCO3A1 (G) 18.9   19.5 1.0 (0.8-1.4)   0.794   1.2 (1.0-1.4)   0.027 
 
rs10184015 in SOS1 (A)   8.2     9.3 1.2 (0.8-1.7)   0.483   1.3 (1.0-1.7)   0.075 
 
rs3755071 in SRBD1 (G) 21.6   25.4 1.2 (1.0-1.6)   0.115   1.0 (0.7-1.4)   0.952 
 
rs16985967 in TTC28 (T) 10.0   10.2 1.0 (0.7-1.5)   0.910   1.5 (0.9-2.4)   0.103 
MAF, minor allele frequency; OR, odds ratio; CI, confidence interval; TDT, transmission disequilibrium 
test; NT, minor allele not transmitted; T, minor allele transmitted; athe least frequent allele in the 
controls of the discovery sample. 
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Suppl. table 8.  Primer and reporter sequences for the custom designed Taqman assays, ID 
numbers of the Taqman SNP genotyping assays, and oligonucleotide primers 
for the real-time PCR reactions. 
 
SNP / Gene 
 
 
Sequence / Taqman SNP genotyping assay ID 
 
 
rs6607499 upstream of KIAA2022 
 
 
 Forward primer GAGTGGAATTTCTGGGTCATATGGA 
 Reverse primer TGGTGCAGCTTCTATGGAAAACA 
 Reporter 1 CATTTGGAGTAACTATCAGAC 
 Reporter 2 ATTTGGAGTAACTGTCAGAC 
 
rs7085066 in SLC16A12 
 
 
 Forward primer CCAGAGACCAAAATGGAACTGAAGT 
 Reverse primer AAGAGTAAGGGCGTGAAATAACCT 
 Reporter 1 CACCAACAAGAGCACC 
 Reporter 2 CACCAACAACAGCACC 
 
rs7063116 upstream of DGKK  
 
 
 Assay ID C_196656_10 
 
rs1934179 in DGKK  
 
 
 Assay ID C_12116498_10 
 
rs1880386 in GRID1 
 
 
 Assay ID C_12127943_10 
 
rs12660161 downstream of MTHFD1L  
 
 
 Assay ID C_11414015_20 
 
rs4705372 in PPARGC1B  
 
 
 Assay ID C_27948404_10 
 
rs1022357 in SLCO3A1 
 
 
 Assay ID C_8719491_10 
 
rs10184015 in SOS1 
 
 
 Assay ID C_30456791_10 
 
rs3755071 in SRBD1 
 
 
 Assay ID C_2773842_10 
 
rs16985967 in TTC28 
 
 
 Assay ID C_34310741_10 
 
GAPDH (PCR product size: 160bp) 
 
 
 Forward primer CATGTTCGTCATGGGTGTGAACCA 
 Reverse primer AGTGATGGCATGGACTGTGGTCAT 
 
DGKK (PCR product size: 160bp) 
 
 
 Forward primer AGAAGAGATGAACACCCAGGGCAA 
 Reverse primer GCAGGTTTGGCAAGGAGATGGTTT 
bp, basepairs. 
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Supplementary note 
 
Dutch discovery sample 
AGORA project 
The AGORA (Aetiologic research into Genetic and Occupational/environmental Risk factors for 
Anomalies in children) project of the Radboud University Nijmegen Medical Centre (RUNMC), 
Nijmegen, The Netherlands, is building a data- and biobank with questionnaire data and DNA 
samples from patients with a congenital malformation or childhood cancer and their parents. 
For the current study, DNA was available of 679 hypospadias cases born between 1980 and 
2007, collected within the AGORA biobank until 2007. All cases were living in the catchment 
area of this hospital, which is Nijmegen and surrounding area. The majority of the cases were 
of European descent (83%), whereas descent was not European (3%) or unknown (14%) for the 
remaining cases. We excluded non-European cases from the analyses. Medical records of all 
cases were reviewed to identify information on syndromal hypospadias cases, to collect clinical 
characteristics of patients, and to determine anatomical location of the urethral opening. The 
location of the urethral opening was determined by experienced pediatric urologists before or 
during surgery. For the current study, anatomical location was subdivided into two categories: 
anterior and middle hypospadias (anterior cases with hypospadias sine hypospadias, glandular 
and (sub)coronal urethral openings and middle cases with penile urethral openings) and 
posterior hypospadias (cases with penoscrotal, scrotal, and perineal urethral openings). The 
Arnhem-Nijmegen Regional Committee on Research Involving Human Subjects approved the 
AGORA project. All participants and/or their parents gave written informed consent for 
participation in the study.  
 
Nijmegen Biomedical Study 
We obtained controls from the Nijmegen Biomedical Study, a population-based survey 
conducted by the Department of Epidemiology, Biostatistics and HTA and the Department of 
Clinical Chemistry of the RUNMC in 2003. Age and sex stratified randomly selected inhabitants 
of the municipality of Nijmegen (n = 22,500) received an invitation to fill out a postal 
questionnaire on lifestyle and medical history, and to donate blood samples. The response to 
the questionnaire was 42% (n = 9,373), whereas 72% (n = 6,747) of the respondents also 
donated blood samples2. We selected the 596 youngest males of Dutch descent for the current 
study. None of them reported hypospadias or penile surgery in the questionnaires. The 
Arnhem-Nijmegen Regional Committee on Research Involving Human Subjects approved the 
Nijmegen Biomedical Study. All participants gave written informed consent for participation in 
the study.  
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Dutch replication sample 
Of the 515 cases that were assigned to one of the eight pools, only 436 could be pooled. The 
remaining 79 cases served as a replication sample, supplemented with 54 cases of European 
descent with isolated anterior or middle hypospadias collected in the AGORA project in 2008 
and 2009. 
 
Swedish replication sample 
Swedish nonsyndromic hypospadias patients from the Karolinska University Hospital, 
Stockholm, Sweden, selected through medical records, served as a second replication sample. 
In total, DNA samples were collected from 356 patients for the replication study, of which we 
selected 266 samples from patients with anterior or middle hypospadias. DNA from 222 
ethnically comparable anonymous healthy male voluntary blood donors at Karolinska 
University Hospital, Sweden, served as a control group, as well as 180 DNA samples from 
placentas taken after birth of a child without a visible malformation. The Ethics Committee at 
Karolinska Institutet approved the study protocol and all participants or parents gave written 
informed consent for participation in the study.  
 
DNA Pooling 
DNA was extracted from blood (n = 980) or saliva (n = 295, Oragene, DNA Genotek Inc.) using 
standard methods. We created eight case pools, after exclusion of six syndromal cases, 22 
cases of non-European descent, 87 cases with posterior hypospadias, and 49 cases with 
unknown localization of the urethral opening. The remaining 515 cases were assigned to one of 
the eight pools based on the source of DNA (blood or saliva) and the localization of the urethral 
opening. Controls were randomly assigned to one of eight control pools.  
 
For each pool, we diluted DNA samples to approximately 100 ng μl -1 in one 96-wells plate. 
Sixteen case samples were excluded due to low concentration (< 50 ng μl -1). Before pooling, we 
verified DNA integrity of the samples by gel electrophoresis. Three case and nineteen control 
samples showed band smearing, which is evidence of DNA degradation, and were excluded. 
We tested DNA quality of the diluted samples using 5’-nuclease TaqMan SNP genotyping assays 
for two SNPs (rs6932902 in ESR1: C_2823640_10 and rs11119982 in ATF3: C_27262262_10, 
Applied Biosystems). One case sample failing both assays was excluded.  
 
Genomic DNA of each sample was quantified in triplicate using PicoGreen (Molecular Probes). 
We only included DNA samples from which reliable triplicate readings could be obtained, 
indicated by less than 10% difference between the readings, in the pools. This led to the 
exclusion of 59 case and 83 control samples. Finally, 436 case and 494 control samples could be 
pooled in eight case and eight control pools. We added equal quantities of DNA from each 
sample to the pools, with a minimum volume of 5 µl, which we considered the minimum 
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volume that could be pipetted sufficiently accurately. Supplementary Figure 1 shows a 
flowchart of the collection, selection, and exclusion of cases for this study. Clinical charac-
teristics of the pooled patients (discovery sample) are displayed in Supplementary Table 1. 
 
We tested accuracy of the pools by comparing the allele frequencies of the individually 
genotyped SNPs (rs6932902 in ESR1 and rs11119982 in ATF3) in the individuals contributing to 
a pool, with the allele frequencies of these SNPs determined in the respective pool. The pools 
and an individual heterozygote were allelotyped using the same allele-specific Taqman probes 
in a real-time PCR 20 times. PCR reactions were carried out in 96-wells plates in a 10 μl volume 
containing 10 ng genomic DNA, 5 μl Taqman Universal PCR master mix, 0.125 μl assay mix and 
MilliQ. The PCR reaction consisted of an initial denaturation step at 95°C for 10 min, followed 
by 40 cycles of denaturation at 92°C for 15 sec, and annealing and extension at 60°C for 60 sec. 
During PCR, allele-specific fluorescence was measured on an ABI 7500 FAST (Applied 
Biosystems). Ct values indicate the cycle time that an allele needs to produce a detectable 
amount of fluorescent signal. This is an indication of the initial quantity of the allele in the pool. 
The delta Ct value is the difference in cycle time that each of the alleles needs to produce a 
detectable amount of fluorescent signal, which is an indication of the proportion of both alleles 
in the pools3. We averaged delta Ct values in the pools across the 20 measurements and 
calculated allele frequencies after correcting for unequal detection of the two alleles based on 
the average delta Ct value in the heterozygote. The allele frequency determined in the 
individual samples differed on average only 1.2% from the allele frequency determined in the 
pools. Therefore, we concluded that the pools accurately reflected the allele distributions of 
the samples, meaning that the pools appear to be correctly constructed with equal amounts of 
DNA from all samples.  
 
Derivation of allele frequency estimates from microarray analysis 
We used the SNPMaP package4 in the statistical software program R (http://www.R-
project.org) to calculate Relative Allele Signal (RAS) scores for each SNP from the CEL files 
generated by the Affymetrix GeneChip Command Console. Using this package, RAS scores were 
calculated by dividing the signal intensity of allele A by the sum of the signal intensities of 
alleles A and B (RAS = A / (A + B)), the method most commonly used in the literature. The signal 
intensities of allele A and B should be the same in a heterozygous individual (equivalent to a 
pool with a 50% allele frequency), however, due to differential amplification and hybridization, 
this is rarely the case. Therefore, corrections need to be made to RAS scores to generate more 
reliable estimates of the allele frequency. The k-correction factor can be calculated for each 
SNP using the ratio of the average signal intensities across all known heterozygotes (k = A / B) 
to obtain a k-corrected raw allele frequency estimate for each SNP (RAFk = A / (A + k*B)). We 
used the SNPMaP package to calculate the RAS values for each SNP from 603 healthy in-house 
controls of European descent assayed individually on the same genotyping platform1. Using the 
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average RAS value from all individuals heterozygous for a SNP, we calculated the k-correction 
factor for each SNP. Using these k-correction factors, RAFk was calculated.  
 
Quality control 
We excluded the worst performing 5% of the measurements, indicated by the biggest 
difference between the RAFk estimates from the duplicate measurements (> 0.07). Thereafter, 
we averaged RAFk and RAS across the remaining duplicate measurements to obtain estimates 
for each SNP.   
 
A SNP-specific variance was calculated across the RAFk values of the case pools and of the 
control pools. Furthermore, we averaged RAFk values across case pools with DNA extracted 
from blood and case pools with DNA extracted from saliva to obtain a RAFk estimate for each of 
these two types of DNA origins. SNPs with a difference between these two estimates above the 
95th percentile (> 0.043) were excluded. In addition, we excluded SNPs with a variance in the 
case or control pools above the 95th percentile (> 0.0018 or > 0.0017, respectively) and SNPs 
with a minor allele frequency below 5% in the individually genotyped in-house controls. A total 
of 574,400 SNPs passed quality control steps and were included in the association analyses. 
 
Selection of SNPs eligible for individual genotyping in the discovery sample 
We used several criteria to select SNPs from the pooled GWAS eligible for individual 
genotyping in the discovery sample to validate the results. First of all, SNPs were required to 
appear in the top 200 ranks for all three statistical tests used, which resulted in 50 eligible SNPs 
(Supplementary Table 2). Secondly, SNPs had to map in or near a known gene (< 50 kb), as 
determined by the annotation data provided by Affymetrix, leaving 32 eligible SNPs. This 
criterion increases the biological interpretability of findings, although we are aware of the risk 
of overlooking associations with intergenic SNPs that may lie in regulatory sequences or yet 
unknown genes. Finally, for the remaining eligible SNPs, we examined whether they were in 
high linkage disequilibrium (LD) (r2 > 0.8) with other SNPs on the array using data from the in-
house controls. If so, the average P-values from the three statistical tests were calculated for 
the SNPs in high LD with an eligible SNP.  
 
We divided eligible SNPs into three groups; 1: A group with supporting evidence defined as at 
least half of the SNPs in high LD having a low average P-value (< 0.22, the 10th percentile of the 
average P-values of all 574,400 SNPs), 2: A group with reduced evidence defined as at least half 
of the SNPs in high LD having a high average P-value, and 3: A group with no supporting 
evidence because of no SNPs in high LD. For individual genotyping in the discovery sample, we 
selected the fourteen eligible SNPs with supporting evidence and the four eligible SNPs with no 
supporting evidence, but with a minor allele frequency above 10% in the individually 
genotyped in-house controls. Furthermore, we selected two additional SNPs with no 
supporting evidence, the SNPs near MTHFD1L and DIAPH3, because we considered these to be 
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promising functional candidate genes. DIAPH3 is an important factor in epithelial cell 
migration5, and a previous study suggested an association of hypospadias with intake of certain 
nutrients related to one-carbon metabolism6, in which the MTHFD1L gene plays a role. Thus, 
20 SNPs were eligible for individual genotyping in the discovery sample.  
 
Expression of DGKK 
Preputial skin samples 
Excess preputial skin was obtained from fourteen  patients with hypospadias undergoing 
surgical repair and from ten age-matched controls undergoing elective circumcision between 
January 2004 and June 2004 at the Department of Urology of the University of California, San 
Francisco, CA, USA. Patients with undescended testis, intersex condition or known endocrine 
abnormalities were excluded from the study. No patients received preoperative testosterone 
treatment.  The institutional Committee on Human Research at the University of California, San 
Francisco approved this study and all parents gave written informed consent for participation 
in the study.  
 
RNA preparation, reverse transcription and real-time PCR 
We isolated RNA from the preputial skin samples using the QIAGEN RNeasy Midi Kit (QIAGEN 
Inc.). The manufacturer’s protocol was modified to eliminate any contaminating protein and 
DNA by adding Proteinase K (Roche Diagnostics GmbH) and incubation at 55C for 20 min, and 
by adding RNase-free DNase I (QIAGEN Inc.), which was incubated at room temperature for 15 
min. RNA quantity and purity were measured using a Nanodrop spectrophotometer (Thermo 
Fisher Scientific Inc.) and RNA integrity was visualized in agarose gels by the 28s and 18s 
ribosomal RNA bands. We performed the reverse transcription (RT) polymerase chain reaction 
(PCR) according to the standard protocol. Briefly, 2.5 µg RNA was reverse transcribed in a 20 µl 
reaction volume and RT products were diluted 4-fold with TE buffer (10 mM Tris-HCI, pH 8, 1 
mM EDTA).  
 
We designed real-time PCR primers according to target gene sequences published in the NCBI 
nucleotide sequence database (Supplementary Table 8) and these were synthesized by 
Integrated DNA Technologies Inc. Real-time PCR was performed in a 20 μl reaction volume 
containing 20 ng template DNA, 1 × Power SYBR Green PCR master mix (Applied Biosystems) 
and 300 nM primers. Amplification was carried out in 96-wells plates in a 7300 Fast sequence 
detection system (Applied Biosystems) with the manufacturer's default thermal profile (50°C 
for 2 min, 95°C for 10 min, and 40 cycles of 95°C for 15 sec and 60°C for 1 min) followed by a 
dissociation stage (95°C for 15 sec, 60°C for 15 sec, followed by a slow ramp to 95°C). We 
performed primer titration and dissociation experiments to prevent primer dimers or false 
amplicons from interfering with the result. After the RT PCR experiment, Ct numbers were 
extracted for both the reference gene and the target gene with auto baseline and manual 
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threshold using standard 7300 Fast software. Expression levels of DGKK were reported relative 
to GAPDH. We repeated the PCR three times for each sample and averaged results across the 
three measurements when no exceptional outliers were seen. Consequently, two samples 
were averaged across two measurements. 
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